Black Diamond Therapeutics, Inc.

BDTX · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.6%

Institutions72.5%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$70.00M	–	–	–	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$12.52M	-$78.78M	-$86.46M	-$92.83M	-$126.87M	-$69.57M	-$29.33M
Operating income as a percentage of revenue.	17.9%	–	–	–	–	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$22.37M	-$69.68M	-$82.44M	-$91.17M	-$125.60M	-$67.25M	-$35.26M
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.39	$-1.27	$-1.88	$-2.52	$-3.47	$-2.05	$-16.99
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.39	$-1.27	$-1.88	$-2.52	$-3.47	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$20.99M	$36.44M	$56.22M	$34.31M	$65.80M	$34.60M	$154.67M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$143.01M	$122.64M	$158.57M	$156.25M	$247.68M	$329.67M	$158.29M
Everything the company owes — debt, unpaid bills, and other obligations.	$30.80M	$39.35M	$41.83M	$40.56M	$51.78M	$21.91M	$4.88M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$112.21M	$83.28M	$116.74M	$115.69M	$195.90M	$307.76M	-$47.16M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$29.61M	-$62.30M	-$66.72M	-$85.08M	-$100.15M	-$52.15M	-$24.67M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	$0	$33000	$192000	$2.71M	$142000	$21000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	-$62.30M	-$66.75M	-$85.27M	-$102.86M	-$52.29M	-$24.70M

	You	Peer avg
P/E	–	2.9
Revenue Growth	–	-42.8%
ROE	-37.2%	-47.2%

Black Diamond Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison